A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial - 06/08/11
, Mauricio G. Cohen, MD b, l, Roxana Mehran, MD c, l, Christopher E. Buller, MD d, l, Christoph Bode, MD e, l, Jan H. Cornel, MD f, l, Jarosław D. Kasprzak, MD g, l, Gilles Montalescot, MD h, l, Diane Joseph a, William A. Wargin, PhD i, Christopher P. Rusconi, PhD j, Steven L. Zelenkofske, DO k, l, Richard C. Becker, MD a, l, John H. Alexander, MD, MHS a, lRésumé |
Anticoagulants are the cornerstone of current acute coronary syndrome (ACS) therapy; however, anticoagulation regimens that aggressively reduce ischemic events are almost uniformly associated with more bleeding. REG1, an anticoagulation system, consists of RB006 (pegnivacogin), an RNA oligonucleotide factor IXa inhibitor, and RB007 (anivamersen), its complementary controlling agent. Phase I and IIa studies defined predictable relationships between doses of RB006, RB007, and degree of antifactor IX activity. The efficacy and safety of REG1 for the treatment of patients with ACS managed invasively and the safety of reversing RB006 with RB007 after cardiac catheterization are unknown. Randomized, partially-blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system compared to unfractionated heparin or low molecular heparin in subjects with acute coronary syndrome (RADAR) is designed to assess both the efficacy of the anticoagulant RB006 and the safety of a range of levels of RB006 reversal with RB007. The objectives of RADAR are (1) to determine the safety of a range of levels of RB006 reversal with RB007 after catheterization, (2) to confirm whether a dose of 1 mg/kg RB006 results in near-complete inhibition of factor IXa in patients with ACS, and (3) to assess the efficacy of RB006 as an anticoagulant in patients with ACS undergoing percutaneous coronary intervention.
Le texte complet de cet article est disponible en PDF.Plan
| Vladimir Dzavik, MD, served as guest editor for this article. |
|
| RCT reg no. NCT00932100. |
Vol 161 - N° 2
P. 261 - février 2011 Retour au numéro
Article précédent
- Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes
- Sanjit S. Jolly, Kari Niemelä, Denis Xavier, Petr Widimsky, Andrzej Budaj, Vicent Valentin, Basil S. Lewis, Alvaro Avezum, Philippe Gabriel Steg, Sunil V. Rao, John Cairns, Susan Chrolavicius, Salim Yusuf, Shamir R. Mehta
- Associations between cardiovascular parameters and uteroplacental Doppler (blood) flow patterns during pregnancy in women with congenital heart disease: Rationale and design of the Zwangerschap bij Aangeboren Hartafwijking (ZAHARA) II study
- Ali Balci, Krystyna M. Sollie, Barbara J.M. Mulder, Monique W.M. de Laat, Jolien W. Roos-Hesselink, Arie P.J. van Dijk, Elly M.C.J. Wajon, Hubert W. Vliegen, Willem Drenthen, Hans L. Hillege, Jan G. Aarnoudse, Dirk J. van Veldhuisen, Petronella G. Pieper
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?